A nasal spray that forms a barrier against COVID-19 is due to be launched locally next week, providing a secondary layer of protection, particularly in crowded, enclosed and high-risk settings.
Touted as an additional, clinically-proven tool in the battle against the coronavirus, the Israeli product, Taffix™ (Powder) Spray Device, claims to offer 97 per cent shielding from respiratory viruses in the nasal cavity – also blocking SARS-CoV-2.
Every application works within 50 seconds and gives five-hour protection, the manufacturer, Nasus Pharma said.
It insists, however, that intra-nasal antiviral protection does not replace the wearing of face masks. The company strongly recommends it is used in addition to other preventative health measures, including social distancing, regular hand washing and compliance with other government restrictions.
Spanish regulators BAN £51 nasal spray that studies show may cut the risk of catching Covid because there is no proof it is safe
Taffix s nasal spray product is sold in packs of four for as much as £51 on Amazon
But the Spanish medicines agency has withdrawn the product from shelves
They say there is not enough clinical evidence the spray was safe and effective
Un aerosol nasal israelí redujo la infección por COVID-19 en un 78 por ciento infobae.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from infobae.com Daily Mail and Mail on Sunday newspapers.
The nasal spray, Taffix, coats the inside of the nose to stop the infection in its tracks and creates a more acidic environment for viruses like Covid-19 to survive
A readily-available nasal spray may have prevented Jews from catching Covid at a religious festival in Israel last year, a study has suggested.
The £51 spray, sold in a pack of four, called Taffix, is said to coat the inside of the nose in an acidic powder that makes it difficult for viral particles to penetrate.
The densely populated city of Bney Brak, four miles (6.3km) east of Tel Aviv, saw its infection rate soar from 18 per cent of the population to 28 per cent following the Jewish new year last September.